Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06750185 | Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 248 | BioNTech SEINDUSTRY | 2 | Sep 9, 2026 | clinicaltrials |
| NCT07436728 | A Study of TAK-505 in Adults With Solid Tumors | recruiting | Phase 1 / Phase 2 | 151 | TakedaINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07811037 |
| A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Efficacy of SGT003 in Patients With Advanced Solid Tumors |
| recruiting |
| Phase 1 / Phase 2 |
| 332 |
| Beijing Sungen Biomedical Technology Co., LtdINDUSTRY |
| 1 |
| Sep 9, 2026 |
| clinicaltrials |
| NCT04970121 | Efficacy and Safety of Duloxetine in Chinese Solid Tumor Patients With Taxanes-induced Painful Peripheral Neuropathy | recruiting | Phase 2 | 100 | Yan Yang, MD, Ph.DOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT05732831 | Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | recruiting | Phase 1 / Phase 2 | 225 | Tango Therapeutics, Inc.INDUSTRY | 3 | Sep 8, 2026 | clinicaltrials |
| NCT07446855 | Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours(PARTHENON) | recruiting | Phase 1 / Phase 2 | 180 | AstraZenecaINDUSTRY | 6 | Sep 8, 2026 | clinicaltrials |
| NCT05315700 | Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration | recruiting | Phase 1 / Phase 2 | 350 | ORIC PharmaceuticalsINDUSTRY | 10 | Sep 4, 2026 | clinicaltrials |
| NCT05688605 | A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 18 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06311214 | Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial) | recruiting | Phase 2 | 500 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06499350 | A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 33 | FindCure Biosciences (ZhongShan) Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07038343 | AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) | recruiting | Phase 1 / Phase 2 | 480 | Avenzo Therapeutics, Inc.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07545265 | SKB565 for Injection in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07602842 | A Study of IDP-001 in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 132 | InduPro, Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05868226 | PRE-ISPY Phase I/II Oncology Platform Program(PRE-ISPY) | recruiting | Phase 1 / Phase 2 | 280 | QuantumLeap Healthcare CollaborativeOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06795412 | Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 220 | Pyxis Oncology, IncINDUSTRY | 3 | Sep 2, 2026 | clinicaltrials |
| NCT04570423 | A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy | recruiting | Phase 2 | 40 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05958121 | IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 400 | Immatics Biotechnologies GmbHINDUSTRY | 2 | Sep 1, 2026 | clinicaltrials |
| NCT06833008 | A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 85 | IpsenINDUSTRY | 4 | Sep 1, 2026 | clinicaltrials |
| NCT07213817 | A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours | recruiting | Phase 1 / Phase 2 | 114 | IpsenINDUSTRY | 3 | Sep 1, 2026 | clinicaltrials |
| NCT07700160 | First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 230 | VelaVigo Bio IncINDUSTRY | 3 | Sep 1, 2026 | clinicaltrials |
| NCT05830058 | Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma | recruiting | Phase 2 | 32 | City of Hope Medical CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06193902 | LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.(AERIAL) | recruiting | Phase 1 / Phase 2 | 17 | Leucid BioINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06682780 | A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 320 | LaNova Medicines LimitedINDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT05038150 | Study of SGN1 in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 70 | Guangzhou Sinogen Pharmaceutical Co., LtdOTHER | 2 | Aug 27, 2026 | clinicaltrials |
| NCT05103345 | Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 70 | Guangzhou Sinogen Pharmaceutical Co., LtdOTHER | 2 | Aug 27, 2026 | clinicaltrials |
| NCT05785039 | A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors | recruiting | Phase 2 | 76 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06492070 | Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers | recruiting | Phase 2 | 70 | Emory UniversityOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06783647 | A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)] | recruiting | Phase 2 | 250 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07186842 | A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9 | recruiting | Phase 1 / Phase 2 | 245 | BioNTech SEINDUSTRY | 5 | Aug 27, 2026 | clinicaltrials |
| NCT04851119 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | recruiting | Phase 1 / Phase 2 | 147 | Children's Oncology GroupNETWORK | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06975293 | STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas | recruiting | Phase 1 / Phase 2 | 107 | STORM Therapeutics LTDINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07193511 | BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001) | recruiting | Phase 1 / Phase 2 | 355 | Avenzo Therapeutics, Inc.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07594626 | BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion | recruiting | Phase 1 / Phase 2 | 72 | Northwestern UniversityOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06417554 | A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 80 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05701306 | APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06885281 | A Study of ZL-1310 in Participants With Selected Solid Tumors | recruiting | Phase 1 / Phase 2 | 166 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06154291 | FIH XON7 in Advanced/Metastatic Solid Tumors(FIPO23) | recruiting | Phase 1 / Phase 2 | 255 | Xenothera SASINDUSTRY | 2 | Aug 20, 2026 | clinicaltrials |
| NCT06741644 | A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 800 | CStone PharmaceuticalsINDUSTRY | 3 | Aug 20, 2026 | clinicaltrials |
| NCT04104776 | A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | recruiting | Phase 1 / Phase 2 | 300 | Novartis PharmaceuticalsINDUSTRY | 7 | Aug 19, 2026 | clinicaltrials |
| NCT06144671 | Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 78 | Grit BiotechnologyINDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07246863 | Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC | recruiting | Phase 2 | 131 | CatalYm GmbHINDUSTRY | 7 | Aug 19, 2026 | clinicaltrials |
| NCT05919264 | FOG-001 in Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 619 | Parabilis Medicines, Inc.INDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT06616766 | A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946 | recruiting | Phase 1 / Phase 2 | 201 | Yuhan CorporationINDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT06635785 | Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors(BiPAVE-001) | recruiting | Phase 1 / Phase 2 | 387 | OncoC4, Inc.INDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07440290 | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06425926 | Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 117 | Georgiamune IncINDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
Data updated 21 days agoSource updated Sep 9, 2026source: clinicaltrials